



PCT/GB 00 / 02302

89/26712



INVESTOR IN PEOPLE

4

GB00/2302

**PRIORITY  
DOCUMENT**SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

REC'D 12 SEP 2000

WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

I also certify that by virtue of an assignment registered under the Patents Act 1977, the application is now proceeding in the name as substituted.

I further certify that the attached copy of the request for grant of a Patent (Form 1/77) bears an amendment, effected by this office, following a request by the applicant and agreed to by the Comptroller-General.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated

11th August 2000





INVESTOR IN PEOPLE

GB9918741.1

By virtue of a direction given under Section 32 of the Patents Act 1977, the application is proceeding in the name of  
**PROTHERICS MOLECULAR DESIGN LIMITED,**  
Beechwood House,  
Lyme Green Business Park,  
Macclesfield,  
Cheshire,  
SK11 0JL,  
United Kingdom

[ADP No. 07935026001]



The  
Patent  
Office10AUG99 E468272-1 D90027  
P01 000 0.00 - 9918741.1

1/77

## Request for grant of a patent

See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office  
Cardiff Road  
Newport  
Gwent NP9 1RH

1. Your reference	44.3.70304/003		
2. Patent application number (The Patent Office will fill in this part)	9918741.1		
3. Full name, address and postcode of the or of each applicant (underline all surnames)	Proteus Molecular Design Limited Beechfield House Lyme Green Business Park Macclesfield Cheshire SK10 0JL		
Patents ADP number (if you know it)			
If the applicant is a corporate body, give country/state of incorporation	UK		
4. Title of the invention	Compounds		
5. Name of your agent (if you have one)	Frank B. Dehn & Co. MARTIN A. HAY		
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)	179 Queen Victoria Street London EC4V 4EL MACCLESFIELD CHESHIRE SK11 6UP		
Patents ADP number (if you know it)	166001		
6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (day / month / year)
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application	Date of filing (day / month / year)	
8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if: a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body. See note (d))	yes		

## Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

-

Description

46

Claim(s)

-

Abstract

-

Drawing(s)

-

10. If you are also filing any of the following, state how many against each item.

Priority documents

-

Translations of priority documents

-

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

-

Request for preliminary examination and search (*Patents Form 9/77*)

-

Request for substantive examination (*Patents Form 10/77*)

-

Any other documents  
(please specify)

-

11.

I/We request the grant of a patent on the basis of this application.

Signature

Date 9 August 1999

12. Name and daytime telephone number of person to contact in the United Kingdom

Julian Cockbain  
0171 206 0600

### Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

### Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s) of the form. Any continuation sheet should be attached to this form.
- If you have answered 'Yes', Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

70304/003.605

Compounds

5 This invention relates to compounds which are inhibitors of serine proteases and to pharmaceutical compositions thereof and their use in the treatment of the human or animal body.

10 The serine proteases are a group of proteolytic enzymes which have a common catalytic mechanism characterized by a particularly reactive Ser residue. Examples of serine proteases include trypsin, tryptase, chymotrypsin, elastase, thrombin, plasmin, kallikrein, Complement C1, acrosomal protease, lysosomal protease, cocoonase,  $\alpha$ -lytic protease, protease A, protease B, 15 serine carboxypeptidase II, subtilisin, urokinase, Factor VIIa, Factor IXa, and Factor Xa. The serine proteases have been investigated extensively over a period of several decades and the therapeutic value of inhibitors of serine proteases is well understood.

20 Serine protease inhibitors play a central role in the regulation of a wide variety of physiological process including coagulation, fibrinolysis, fertilization, development, malignancy, neuromuscular patterning and inflammation. It is well known that 25 these compounds inhibit a variety of circulating proteases as well as proteases that are activated or released in tissue. It is also becoming clear that serine protease inhibitors inhibit critical cellular processes, such as adhesion, migration, free radical 30 production and apoptosis. In addition, animal experiments indicate that intravenously administered serine protease inhibitors, variants or cells expressing serine protease inhibitors, provide a protective effect against tissue damage.

35 Serine protease inhibitors have also been predicted to have potential beneficial uses in the treatment of disease in a wide variety of clinical areas such as

oncology, neurology, haematology, pulmonary medicine, immunology, inflammation and infectious disease.

In particular serine protease inhibitors may be beneficial in the treatment of thrombotic diseases, asthma, emphysema, cirrhosis, arthritis, carcinoma, melanoma, restenosis, atheroma, trauma, shock and reperfusion injury.

Thus for example an inhibitor of Factor Xa has value as a therapeutic agent as an anticoagulant, e.g. in the treatment and prevention of thrombotic disorders. The use of a Factor Xa inhibitor as an anticoagulant is desirable in view of the selectivity of its effect. Many clinically approved anticoagulants have been associated with adverse events owing to the non-specific nature of their effects on the coagulation cascade.

Also, there are well-known associations of  $\alpha_1$  protease inhibitor deficiency with emphysema and cirrhosis and C1 esterase inhibitor deficiency with angioedema.

We have now found that certain aromatic compounds carrying bulky lipophilic side chains are particularly effective as inhibitors of serine proteases, especially proteases with negatively charged P1 specificity pockets, and most especially the serine proteases thrombin, trypsin, urokinase, Factor VIIa and most importantly Factor Xa. The Factor Xa inhibitors of this invention are potentially useful for the prophylaxis or treatment of thrombotic disorders such as amongst others venous thrombosis, pulmonary embolism, arterial thrombosis, myocardial ischaemia, myocardial infarction, and cerebral thrombosis. They potentially have benefit in the treatment of acute vessel closure associated with thrombolytic therapy and restenosis, e.g. after transluminal coronary angioplasty or bypass grafting of the coronary or peripheral arteries and in the maintenance of vascular access patency in long term hemodialysis patients.




Factor Xa inhibitors of this invention may, with benefit, form part of a combination therapy with an anticoagulant with a different mode of action or with a thrombolytic agent.

5 We have previously reported in WO99/11657 and WO99/11658 that certain benzamidine and isoquinoline derivatives carrying a bulky lipophilic side chain are excellent inhibitors of serine proteases. Surprisingly, we have now found certain other aromatic compounds also  
10 show inhibitory activity against serine proteases, in particular Factor Xa, despite the lack of the amidino or 1-aminoisoquinoline functionality previously believed to be crucial for activity as a factor Xa inhibitor.

The compounds of the invention are thus likely to  
15 be available for administration orally. Also, it has been found that the compounds of the invention perform excellently in the prothrombin time assay (PT) when compared to aminoisoquinolines of similar factor Xa activity. The PT assay is a coagulation assay and it is  
20 widely accepted that direct acting Factor Xa inhibitors which perform well in the PT assay are more likely to be good antithrombotics.

In WO99/09053 certain 2-aminobenzamide compounds are disclosed as potential motilin receptor antagonists  
25 and in US 3268513 similar 2-aminobenzamide compounds are suggested as potential antibacterial agents. However, the novel compounds of the present invention have not before been suggested as potential serine protease inhibitors.

30 Thus viewed from an one aspect the invention provides a serine protease inhibitor compound of formula (I)



(where  $R_2$  represents a 5 or 6 membered aromatic carbon ring optionally interrupted by a nitrogen, oxygen or sulphur ring atom, optionally being substituted in the 3 or 4 position by halo, nitro, haloalkoxy, amino, cyano, haloalkyl, alkylthio, alkenyl, alkynyl, acylamino or  $R_1$  or the substituents at the 3 and 4 positions taken together form a fused ring which is a 5 or 6 membered carbocyclic or heterocyclic ring optionally substituted by halo, haloalkoxy, haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl, alkynyl or  $R_1$ , and optionally substituted in the position alpha to the X-X.. group (i.e. 6 position for a six membered aromatic ring etc) by amino, hydroxy, halo, alkyl, alkoxy or alkylthio with the proviso that  $R_2$  cannot be isoquinolyl;

each X independently is a C, N, O or S atom or a CO,  $CR_1$ ,  $C(R_1)_2$  or  $NR_1$  group, at least one X being C, CO,  $CR_1$  or  $C(R_1)_2$ ;

each  $R_1$  independently represents hydrogen or hydroxyl, alkoxy, alkyl, aminoalkyl, hydroxyalkyl alkoxyalkyl, alkoxycarbonyl, acyloxymethoxycarbonyl or alkylamino optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl;

L is an organic linker group containing 1 to 5 backbone atoms selected from C, N, O and S, or a branched alkyl or cyclic group;

Y (the  $\alpha$ -atom) is a nitrogen atom or a  $CR_1$  group or Y and L taken together form a cyclic group;

Cy is a saturated or unsaturated, mono or poly cyclic, homo or heterocyclic group, preferably containing 5 to 10 ring atoms and optionally substituted by groups  $R_3$  or phenyl optionally substituted by  $R_3$ ;

each  $R_3$  independently is  $R_1$ , amino, halo, cyano, nitro, thiol, alkylthio, alkylsulphonyl, alkylsulphenyl, triazolyl, imidazolyl, tetrazolyl, hydrazido, alkyl imidazolyl, thiazolyl, alkyl thiazolyl, alkyl oxazolyl, oxazolyl, alkylsulphonamido, alkylamino-sulphonyl, aminosulphonyl, haloalkoxy and haloalkyl;

Lp is a lipophilic organic group, e.g. an alkyl, heterocyclic, alkenyl, alkaryl, cycloalkyl, polycycloalkyl, cycloalkenyl, aryl, aralkyl or haloalkyl group or a combination of two or more such groups optionally substituted by one or more of oxa, oxo, aza, thia, or R<sub>3</sub> groups, preferably a group containing up to 25 carbon atoms;

D is a hydrogen bond donor group; and n is 0, 1 or 2);

or a physiologically tolerable salt thereof, e.g. a halide, phosphate or sulphate salt or a salt with ammonium or an organic amine such as ethylamine or meglumine.

In the compounds of the invention, where the alpha atom is carbon it preferably has the conformation that would result from construction from a D- $\alpha$ -aminoacid NH<sub>2</sub>-CR<sub>1</sub>(Cy)-COOH where the NH<sub>2</sub> represents part of X-X. Likewise the fourth substituent R<sub>1</sub> at an alpha carbon is preferably a methyl or hydroxymethyl group or hydrogen.

In the compounds of the invention, unless otherwise indicated, aryl groups preferably contain 5 to 10 ring atoms optionally including 1, 2 or 3 heteroatoms selected from O, N and S; alkyl, alkenyl or alkynyl groups or alkylene moieties preferably contain up to 6 carbons, e.g. C<sub>1-6</sub> or C<sub>1-3</sub>; cyclic groups preferably have ring sizes of 3 to 8 atoms; and fused multicyclic groups preferably contain 8 to 16 ring atoms.

The linker group from the R<sub>2</sub> group to the alpha atom is preferably selected from -CH=CH-, -CONH-, -CONR<sub>1</sub>-, -NH-CO-, -NH-CH<sub>2</sub>-, -CH<sub>2</sub>-NH-, -CH<sub>2</sub>O-, -OCH<sub>2</sub>-, -COO-, -OC=O- and -CH<sub>2</sub>CH<sub>2</sub>-. Preferably, the X moiety nearest to the alpha atom is an NH or O atom, most preferably a NH group. The X moiety alpha to the aromatic ring is preferably a carbon based group such as CH<sub>2</sub> or CO, preferably CO. Thus a particularly preferred linker X-X is -CONH-. In an alternative embodiment the linker is preferably a -OCH<sub>2</sub>- group.

The alpha atom (Y) is preferably a CH or C(CH<sub>3</sub>) group, especially CH.

The linker group from the alpha atom to the lipophilic group is preferably CO, CH<sub>2</sub>NH, CONR<sub>1</sub>(CH<sub>2</sub>)<sub>m</sub>,  
5 (CH<sub>2</sub>)<sub>m</sub>N(R<sub>1</sub>)CO(CH<sub>2</sub>)<sub>m</sub>, (CH<sub>2</sub>)<sub>m+2</sub>, CO(CH<sub>2</sub>)<sub>m</sub>, (CH<sub>2</sub>)<sub>m</sub>CO, (CH<sub>2</sub>)<sub>m</sub>OC=O,  
(CH<sub>2</sub>)<sub>m</sub>O, CH=CH(CH<sub>2</sub>)<sub>m</sub>, SO<sub>2</sub>, SO<sub>2</sub>NR<sub>1</sub>, SO<sub>2</sub>(CH<sub>2</sub>)<sub>m</sub>, (CH<sub>2</sub>)<sub>m</sub>SO<sub>2</sub> or  
(CH<sub>2</sub>)<sub>m</sub>SO<sub>2</sub>NR<sub>1</sub> (where each m is independently 0 or 1). The  
linker may be optionally branched, for example, to  
10 incorporate a polar functionality. In a preferred  
embodiment Y and L taken together form a cyclic group  
and the alpha atom is therefore a carbon atom. The  
cyclic group can be unsubstituted or substituted and can  
have a ring size of from 3 to 8 atoms. Preferably, the  
cyclic group is a cyclic amide, most preferably wherein  
15 the amide nitrogen of the cyclic amide group is bound to  
the lipophilic group.


The lipophilic group preferably comprises a  
cycloalkyl, azacycloalkyl, diazacycloalkyl, phenyl,  
naphthyl, adamantyl, decalynyl, tetrahydrodecalynyl,  
20 bicycloalkyl, mono- or diazabicycloalkyl, mono- or  
bicyclo heteroaromatic or a linear or branched alkyl,  
alkylene, alkenyl or alkenylene group all optionally  
substituted by one or more groups R<sub>3</sub>, or a combination of  
at least two such groups linked by a spiro linkage or a  
25 single or double bond or by C=O, O, S, SO, SO<sub>2</sub>, CONR<sub>1</sub>,  
NR<sub>1</sub>-CO-, NR<sub>1</sub> linkage. For example, representative  
lipophilic groups include a methyl-cyclohexyl,  
methylcyclohexylmethyl, methylphenylmethyl, phenylethyl,  
benzylpiperidinyl, benzoylpiperidinyl, bispiperidinyl or  
30 phenylpiperazinyl.

Most preferably, the lipophilic group is selected  
from




wherein  $R_3$  is as hereinbefore defined;  
 $m$  represents 0 or 1;  
 $R_4$  represents hydrogen,  $(CH_2)_wCOOH$ ,  $(CH_2)_wCONH_2$ ,  
 $(CH_2)_wCON\alpha$ -AminoAcid;  
 $w$  represents an integer from 0 to 4; and  
 $X$  represents CH or N.  
For example specific lipophilic groups include


10





15



20




25



especially when  $R_8$  represents H, OMe,  $SO_2Me$ , F,  $NO_2$ ,  
 $SO_2N(R_1)_2$ , Cl, OH or a 5 membered heterocyclic group.

Another highly preferred lipophilic group is of  
formula (DP)


35



wherein A represents N or CH and  $R_3$  is as

hereinbefore defined. When the lipophilic group is (DP) it is preferred that the group L represents CO, CH<sub>2</sub> or SO<sub>2</sub>. Also, it is preferred if the R<sub>3</sub> groups in the formula DP are hydrogen.

Hence, preferred compounds of the invention are those of formula (J)




where R<sub>2</sub>, X-X, and Cy are as hereinbefore defined and L represents CO, CH<sub>2</sub> or SO<sub>2</sub>.

15 The hydrogen bond donor group which may be attached to the lipophilic group preferably has a nitrogen or oxygen atom as the donor atom and conveniently is a hydroxyl group, a primary, secondary or tertiary amine, or a primary or secondary imine group (as part of an  
20 amidine or guanidine) or a saturated or unsaturated heterocyclic group containing a ring nitrogen, preferably a group containing 5 to 7 ring atoms. Where the donor atom is a ring nitrogen, the remote portion of the heterocyclic ring may be part of the lipophilic  
25 group.

The cyclic group attached to the alpha carbon is preferably an optionally R<sub>3</sub> substituted phenyl, thienyl or naphthyl group.

30 In one embodiment the aromatic R<sub>2</sub> group is an optionally substituted phenyl, naphthyl, indolyl or isoindolyl group and accordingly, preferred compounds of the invention are of formula (II)

35



(wherein R<sub>5</sub> is amino, hydroxy or hydrogen, and R<sub>6</sub> and R<sub>7</sub> which may be the same or different represent halo, nitro, thiol, cyano, haloalkyl, haloalkoxy, amido, hydrazido, amino, alkylthio, alkenyl, alkynyl or R<sub>1</sub> or taken together form a 5 or 6 membered fused carbocyclic ring or 5 membered heterocyclic ring, which may itself be substituted by R<sub>1</sub>, amino, halo, cyano, nitro, thiol, alkylthio, haloalkyl, haloalkoxy.

Ar is an unsubstituted or substituted aryl group, preferably phenyl;

X-X is -CONH-, -CH<sub>2</sub>CH<sub>2</sub>-, CH<sub>2</sub>O-, -COO-, -CH<sub>2</sub>NH-, -OCH<sub>2</sub>- or -NHCH<sub>2</sub>-, especially -CONH-;

L<sub>1</sub> is a valence bond or an organic linker group containing 1 to 4 backbone atoms selected from C, N, O and S;


Lp<sub>1</sub> is a cycloalkyl, azacycloalkyl, diazacycloalkyl, phenyl, naphthyl, adamantyl, decalinyl, tetrahydrodecalinyl, bicycloalkyl, mono- or diazabicycloalkyl, mono- or bicyclo heteroaromatic or a linear or branched alkyl, alkylene, alkenyl or alkenylene group all optionally substituted by a group R<sub>3</sub>, or a combination of at least two such groups linked by a spiro linkage or a single or double bond or by C=O, O, S, SO, SO<sub>2</sub>, CONR<sub>1</sub>, NR<sub>1</sub>-CO-, NR<sub>1</sub> linkage. For example, representative lipophilic groups include a methylcyclohexyl, methylcyclohexylmethyl, bispiperidinyl, methylphenylmethyl, phenylethyl, benzylpiperidinyl, benzoylpiperidinyl or phenylpiperazinyl and those as hereinbefore described;

D is a hydrogen bond donor group;  
and n is 0, 1 or 2).



In an alternative embodiment the phenyl derivative forming part of the  $R_2$  functionality may instead be a nitrogen heterocyclic group, e.g. pyridine. Thus suitable  $R_2$  groups may be


5



It is preferred that at least one of  $R_6$  and  $R_7$  be other than hydrogen and that  $R_6$ , if present, is preferably a substituent containing one or more polar hydrogens such as hydroxy, amino, alkylamino, aminoalkyl, alkylaminoalkyl, aminocarbonyl, alkylaminocarbonyl, alkylcarboxyamino, hydrazo and alkylhydrazo; alternatively  $R_6$  and  $R_7$  are joined together in the formation of a naphthyl or indolyl or azaindolyl or diazaindolyl group.

It is especially preferred that  $R_6$  be amino and  $R_7$  be chloro, bromo, methyl, methoxy, trifluoromethyl or trifluoromethoxy; or that  $R_6$  and  $R_7$  taken together form an indolyl ring with the NH at the 6-position or taken together form a naphthyl ring.

In a further preferred embodiment the compounds of the invention are of formula (A)



(wherein  $R_5$ ,  $R_6$ ,  $R_7$ , Ar, X-X,  $Lp_1$ ,  $D_n$  are as hereinbefore defined;  $L_2$  is a valence bond or an organic linker group containing 1 to 3 backbone atoms selected from C, N, O and S and  $R_8$  and  $R_9$  are hydrogen or taken together with the carbon atom to which they are attached form a carbonyl group). Again, in an alternative embodiment the phenyl derivative forming part of the  $R_2$  functionality may instead be a nitrogen heterocyclic group, e.g. pyridine.

In one embodiment,  $L_2$  comprises the backbone of an alpha amino acid, the lipophilic group being the side chain of the amino acid. The carboxyl part of the alpha amino acid may be optionally coupled via an amide bond to an amino acid or to a primary or secondary cyclic or


acyclic alkyl amine or diamine or via an ester bond to primary or secondary alcohols.

In one preferred embodiment  $R_8$  and  $R_9$  are hydrogen and  $L_2$  is a  $OC=O$  or  $NHC=O$  group.


5 In a preferred embodiment,  $L_2$  represents a valence bond and the lipophilic group is bound directly to a carbonyl alpha to the alpha atom via a nitrogen atom which forms part of the lipophilic group. Suitable lipophilic groups in this case therefore include  
10 piperidinyl, pyrrolidinyl and piperazinyl. In a preferred embodiment the piperidine or piperazinyl group is further substituted by a phenyl, benzyl, phenoxy, piperidine, pyridine or benzoyl group, optionally substituted on the phenyl ring by one or more  $R_3$  groups.  
15 In a more preferred embodiment a piperazine is substituted with a phenyl group substituted at the 2-position with an electron withdrawing group such as fluoro, nitro, triazolyl, cyano, alkoxycarbonyl, aminocarbonyl, aminosulphonyl, alkylaminosulphonyl and,  
20 especially preferred, alkylsulphonyl; and, at the 4-position, with hydrogen, fluoro, alkoxy or hydroxy. In another more preferred embodiment a piperidine is substituted at the 4-position with 4-piperidine which itself may be substituted on nitrogen by alkyl or  
25 aminocarbonylalkyl or alkylaminocarbonyl alkyl.

In a further embodiment, the lipophilic group has attached a group of the formula  $-COOR_1$  or  $-CON$ -aminoacid or ester derivative thereof.

30 Particularly preferred compounds are those of formula (G)




(wherein Ar, R<sub>6</sub> and R<sub>7</sub> are as hereinbefore defined, R<sub>5</sub> represents hydrogen or amino and ----- represents a cyclic group) or of formula (H)



(wherein R<sub>6</sub> and R<sub>7</sub> are as hereinbefore defined, and R<sub>5</sub> represents hydrogen or amino).

Again, in an alternative embodiment the phenyl derivative forming part of the R<sub>2</sub> functionality in formulae (G) and (H) may instead be a nitrogen heterocyclic group, e.g. pyridine, indole.

In another embodiment the group binding the alpha carbon atom to the lipophilic group comprises a heterocyclic group. Accordingly, preferred compounds of the invention also include those of formula (III)



(wherein R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, Ar, X-X, Lp<sub>1</sub>, D<sub>n</sub> are as hereinbefore defined;

m is 0, 1 or 2;


Het is a 5 or 6-membered heterocyclic group interrupted by 1, 2 or 3 heteroatoms selected from O, N and S optionally substituted by a group R<sub>3</sub>). Again, in an alternative embodiment the phenyl derivative forming part of the R<sub>2</sub> functionality may instead be a nitrogen heterocyclic group, e.g. pyridine.

Where Het is a five membered ring, the two ring

atoms at which it is connected are preferably separated by one ring atom. Where Het is a six-membered ring, the two ring atoms at which it is connected are preferably separated by one or two ring atoms. Representative heterocyclic groups include thiazole, oxazole, oxadiazole, triazole, thiadiazole or imidazole. Where the heterocyclic group is substituted by  $R_3$  this is preferably a  $\text{COOH}$  or  $\text{COOR}_1$  connected to the heterocycle via a valence bond or alkylene chain.


In a further embodiment, the lipophilic group has attached a group of the formula  $-\text{COOR}_1$  or  $-\text{CON}$ -aminoacid or ester derivative thereof.

In an alternative embodiment the main aromatic  $R_2$  ring in the compounds of the invention is a five membered aromatic ring of formula (IV) or (IVa)




(wherein  $R_5$ ,  $R_6$ ,  $R_7$ ,  $\text{X-X}$ ,  $\text{Ar}$ ,  $\text{L}_1$ ,  $\text{Lp}_1$ ,  $\text{D}$  and  $n$  are as hereinbefore described for formula (II) and  $\text{Z}$  represents  $\text{N}$ ,  $\text{O}$  or  $\text{S}$ ). It is preferred that at least one of  $R_6$  and  $R_7$  be other than hydrogen, or that  $R_6$  and  $R_7$  taken together enable the formation of an indolyl, or azaindolyl group or diazaindolyl group. Preferences for other substituents are as for formula (A) above.


Examples of possible fused systems are given below.



Hence in a preferred embodiment the compounds of the invention are of formula C or D




10 (wherein  $R_5$ ,  $R_6$ ,  $R_7$ ,  $Ar$ ,  $X-X$ ,  $Z$ ,  $R_8$ ,  $R_9$ ,  $L_2$ ,  $Lp_1$ ,  $D_n$  are as hereinbefore defined) preferences for  $Ar$ ,  $X-X$ ,  $R_8$ ,  $R_9$ ,  $L_2$ ,  $Lp_1$ ,  $D_n$  are as for formula (A) above; or compounds of formula E or F:



20 (wherein  $Lp_1$  is connected to the carbonyl via a nitrogen atom,  $R_6$ ,  $R_7$ ,  $Ar$ ,  $Z$ ,  $Lp_1$ ,  $D_n$  are as hereinbefore defined and  $R_5$  is hydrogen or amino) preferences for  $Ar$ ,  $Lp_1$ ,  $D_n$  are as for formula (A) above.

25 The compounds of the invention may be prepared by conventional chemical synthetic routes, e.g. by amide bond formation to couple the aromatic function to the alpha atom and to couple the lipophilic function to the alpha atom. Where the alpha atom is a carbon, the cyclic group-alpha atom combination may conveniently  
 30 derive from an alpha amino acid with the aromatic deriving from for example an acid derivative of a compound based on  $R_2$ , e.g. o-amino-benzoic acid. Amide formation from such reagents (in which any amino or hydroxyl function may if desired be protected during  
 35 some or all of the synthesis steps) yields a compound of formula (V).



(where Cy and  $R_2$  are as defined above).

The lipophilic group (and optionally simultaneously  
5 the hydrogen bond donor) may then conveniently be  
introduced by reaction of a compound of formula (V) (or  
another analogous carboxylic acid) optionally after  
transformation into an activated form, e.g. an acid  
chloride or active ester, with a lipophilic group  
10 carrying an amine, hydroxylamine, hydrazine or hydroxyl  
group, e.g. to produce compounds with linkages of  $-\text{CO}-$   
 $\text{NR}_1-$ ,  $-\text{CO}-\text{NR}_1-\text{O}-$ ,  $-\text{CO}-\text{NR}_1-\text{NR}_1-$  and  $-\text{CO}-\text{O}-$  from the alpha  
atom (where it is a carbon) to the lipophilic group.  
Where Y and L taken together form a cyclic amide group  
15 the lipophilic group can be conveniently introduced by  
reacting the compound of formula (V) with a lipophilic  
group carrying a secondary amine with an active side  
chain. Cyclisation can be base induced via nucleophilic  
attack of the alpha atom on a leaving group on the  
20 active side chain. If necessary the amide linkage can  
be reduced using an appropriate reducing agent employing  
the necessary protection depending on whether concurrent  
reduction of the carboxylic acid moiety is also desired.  
Alternatively a compound of formula V or another  
25 analogous carboxylic acid may be transformed into an  
alcohol by reaction with isobutylchloroformate and  
reduction with sodium borohydride.

Such an alcohol, e.g. of formula VI



can be reacted to introduce the lipophilic group by  
reactions such as:

35 alkylation with an alkyl halide in the presence of  
a base;

reaction with diethyl  
azodicarboxylate/triphenylphosphine and a hydroxylated

aryl compound;

by reaction with an activated carboxylic acid (e.g. an acid chloride) or with a carboxylic acid and diethylazodicarboxylate/triphenylphosphine;

5 by reaction with an isocyanate; and

by treatment with methanesulphonyl chloride or trifluoromethanesulphonic anhydride and reaction with an amine, or with a thiol optionally followed by oxidation, e.g. with potassium metaperiodate or hydrogen peroxide.

10 In this way compounds with linkages of  $-\text{CH}_2-\text{O}-$ ,  $-\text{CH}_2-\text{O}-\text{CO}-$ ,  $-\text{CH}_2-\text{O}-\text{CO}-\text{NR}_1-$ ,  $-\text{CH}_2-\text{NR}_1-$ ,  $-\text{CH}_2-\text{S}-$ ,  $-\text{CH}_2-\text{SO}-$  and  $-\text{CH}_2-\text{SO}_2-$  between the alpha carbon and the lipophilic group may be produced.

Alternatively the alcohol can be oxidized to form a  
15 corresponding aldehyde (e.g. by oxidation with manganese dioxide or DMSO/oxalyl chloride or DMSO/ $\text{SO}_3$  or Dess-Martin reagent) which may be reacted to introduce the lipophilic group by reactions such as:

reaction with Wittig reagents or Horner-Emmons  
20 reagents, optionally followed by reduction of the resulting carbon:carbon double bond using  $\text{H}_2/\text{Pd}$ -carbon;

reaction with an organometallic, eg a Grignard reagent, optionally followed by reaction on the resulting hydroxyl group, such as oxidation (eg with  
25  $\text{MnO}_2$ , DMSO/oxalyl chloride or Dess-Martin reagent), alkylation (eg with an alkyl halide in the presence of a base in a solvent such as DMF), arylation (eg with diethylazo dicarboxylate/triphenyl phosphine and a hydroxyaryl compound), ester formation (eg with an acid  
30 chloride or with a carboxylic acid and diethylazido dicarboxylate/triphenyl phosphine), or carbamate formation (eg with an isocyanate);

by reaction with an amine followed by reduction, e.g. with sodium cyanoborohydride;

35 by reaction with a hydrazine; or

by reaction with a carbazide.

In this way compounds with linkages of  $-\text{CH}=\text{CR}_1-$ ,



-CH<sub>2</sub>-CHR<sub>1</sub>-, -CHOH-, -CHR<sub>1</sub>-O-, -CHR<sub>1</sub>-O-CO-, -CHR<sub>1</sub>-O-CO-NR<sub>1</sub>-,  
-CO-, -CH<sub>2</sub>-NR<sub>1</sub>-, -CH=N-NR<sub>1</sub>- and -CH=N-NR<sub>1</sub>-CO-NR<sub>1</sub>- between  
the alpha carbon and the lipophilic group may be  
produced.

5           The transformation of alcohol to amine referred to  
above may be used to produce an amine reagent for  
lipophilic group introduction, e.g. a compound R<sub>2</sub>-CONH-  
CH(Cy)-CH<sub>2</sub>-NR<sub>1</sub>H.

10           Such an amine reagent may be reacted to introduce  
the lipophilic group, e.g. by acylation with an acid  
halide or activated ester, by reaction with isocyanate,  
by reaction with an isothiocyanate, or by reaction with  
a sulphonyl chloride. In this way compounds with  
linkages of -CH<sub>2</sub>NR<sub>1</sub>-CO-, -CH<sub>2</sub>-NR<sub>1</sub>-CO-NR<sub>1</sub>-, -CH<sub>2</sub>NR<sub>1</sub>-CS-NR<sub>1</sub>-  
15 and -CH<sub>2</sub>NR<sub>1</sub>-SO<sub>2</sub>- between the alpha carbon and the  
lipophilic groups may be produced.

          The transformation of acid to amide referred to  
above may be used to produce an amide reagent for  
introduction of the lipophilic group, e.g. a compound R<sub>2</sub>-  
20 CONH-CH(Cy)-CON(R<sub>1</sub>)<sub>2</sub>.

          Such amides may be reacted to introduce lipophilic  
groups, e.g. by reaction with a halo ketone (e.g.  
phenacyl bromide). This provides a linkage



from alpha carbon to lipophilic group.


30           Analogously the amide may be transformed to a  
thioamide by reaction with Lawesson's reagent and then  
reacted with a halo ketone to form a linkage



35           The amide reagent may likewise be transformed to a  
nitrile reagent by dehydration, e.g. with

trifluoroacetic anhydride. The nitrile reagent may be reacted with hydrazine then with acyl halide and then cyclized, (e.g. with trifluoroacetic anhydride) to produce a linkage


5



10

Alternatively it may be treated with hydroxylamine then reacted with acyl halide and cyclized (e.g. with trifluoroacetic anhydride) to produce a linkage

15




20

The hydrazide produced by reaction of a carboxylic acid reagent with hydrazine discussed above may likewise be used as a reagent for lipophilic group introduction, e.g. as a compound of formula  $\text{R}_2\text{-CONH-CH(Cy)-CO-NR}_1\text{-N(R}_1)_2$ .

Thus the hydrazide reagent can be reacted with an acyl halide and cyclized, e.g. with trifluoroacetic anhydride to yield a linkage

25




30


or reacted with an acyl halide or an isocyanate to yield linkages  $\text{-CO-NR}_1\text{-NR}_1\text{-CO-}$  and  $\text{-CO-NR}_1\text{-NR}_1\text{-CO-NR}_1\text{-}$  respectively.

Alternatively the hydrazide may be transformed by reaction with Lawesson's reagent and then reacted with an acyl halide and cyclized (e.g. with trifluoroacetic anhydride) to produce the linkage

35




An alternative route to these compounds is to carry out any of the above chemical reactions to incorporate the lipophilic group (an optional H bond donor) into a protected intermediate such as a compound of formula (VII).



PG=Protecting group

The protecting group may then be removed before coupling of the for example o-amino benzoic acid (optionally protected).

A starting reagent for lipophilic group introduction where the alpha atom is nitrogen may be produced for example by reaction of a beta protected hydrazine (such protection to be chosen as to be compatible with the subsequent reagents to be employed) with phosgene, diphosgene, triphosgene or N,N'carbonyl diimidazole to give a reactive compound of the type:



PG = Protecting group


This intermediate may be used as has been described above for the carboxylic starting reagents where the alpha atom is carbon.

Removal of the protecting group by standard methods and coupling with an activated aryl carboxylic acid will give compounds of the type



(where  $\text{R}_2$ , X, Y, Cy, L, Lp and D are as defined above).

Thus viewed from a further aspect the invention provides a process for the preparation of a compound according to the invention which process comprises coupling a lipophilic group to a compound of formula (VIII)



(wherein  $R_2$ ,  $X$ ,  $Y$  and  $Cy$  are as defined above and  $Z_1$  is a reactive functional group), and optionally subsequently coupling a hydrogen bond donor group to said lipophilic group.

The compounds of the invention may be administered by any convenient route, e.g. into the gastrointestinal tract (e.g. rectally or orally), the nose, lungs, musculature or vasculature or transdermally. The compounds may be administered in any convenient administrative form, e.g. tablets, powders, capsules, solutions, dispersions, suspensions, syrups, sprays, suppositories, gels, emulsions, patches etc. Such compositions may contain components conventional in pharmaceutical preparations, e.g. diluents, carriers, pH modifiers, sweeteners, bulking agents, and further active agents. Preferably the compositions will be sterile and in a solution or suspension form suitable for injection or infusion. Such compositions form a further aspect of the invention.

In particular, it is believed that the compounds of the invention will have excellent oral bioavailability.

Viewed from this aspect the invention provides a pharmaceutical composition comprising a serine protease inhibitor according to the invention together with at least one pharmaceutically acceptable carrier or excipient. The pharmaceutical composition may also optionally comprise at least one further antithrombotic and/or thrombolytic agent.

Viewed from a further aspect the invention provides the use of a serine protease inhibitor according to the

invention for the manufacture of a medicament for use in a method of treatment of the human or non-human animal body (e.g. a mammalian, avian or reptilian body) to combat (i.e. treat or prevent) a condition responsive to said inhibitor.

Viewed from a further aspect the invention provides a method of treatment of the human or non-human animal body (e.g. a mammalian, avian or reptilian body) to combat a condition responsive to a serine protease inhibitor (e.g. a condition such as a thrombotic disorder responsive to a factor Xa inhibitor), said method comprising administering to said body an effective amount of a serine protease inhibitor according to the invention.

The dosage of the inhibitor compound of the invention will depend upon the nature and severity of the condition being treated, the administration route and the size and species of the patient. However in general, quantities of from 0.01 to 100  $\mu\text{mol/kg}$  bodyweight will be administered.

All publications referred to herein are hereby incorporated by reference.

The invention will now be described further with reference to the following non-limiting Examples.

### Experimental

Abbreviations used follow IUPAC-IUB nomenclature. Additional abbreviations are Hplc, high-performance liquid chromatography; DMF, dimethylformamide; DCM, dichloromethane; HAOT, 1-hydroxy-7-azabenzotriazole; HATU, [O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate]; Fmoc, 9-Fluorenylmethoxycarbonyl; HOBt, 1-hydroxybenzotriazole; TBTU, 2-(1H-(benzotriazol-1-yl)-1,1,3,3-tetramethyluroniumtetrafluoroborate; EDCI, 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride;

DIPEA, diisopropylethylamine; Boc, tertiary butyloxycarbonyl; DIPCI, diisopropylcarbodiimide; DBU, 1,8-diazabicyclo[5.4.0]undec-7-ene; TEA, triethylamine; Rink linker, p-[(R,S)- $\alpha$ -[1-(9H-Fluoren-9-yl)methoxyformamido]-2,4-dimethoxybenzyl]phenyl acetic acid; TFA, trifluoroacetic acid; MALDI-TOF, Matrix assisted laser desorption ionisation - time of flight mass spectrometry, RT, retention time. Unless otherwise indicated amino acid derivatives, resins and coupling reagents were obtained from Novabiochem (Nottingham, UK) and other solvents and reagents from Rathburn (Walkerburn, UK) or Aldrich (Gillingham, UK) and were used without further purification. All solution concentrations are expressed as %Vol./%Vol. unless otherwise stated.

**Purification:** Purification was by gradient reverse phase Hplc on a Waters Deltaprep 4000 at a flow rate of 50 ml/min. using a Deltapak C18 radial compression column (40 mm x 210 mm, 10-15 mm particle size). Eluant A consisted of aqTFA (0.1%) and eluant B 90% MeCN in aqTFA(0.1%) with gradient elution (Gradient 1, 0 min. 20%B then 20% to 100% over 36 min., Gradient 2, 0 min. 5%B for 1 min. then 5%B to 20%B over 4 min., then 20% to 60% over 32 min. or Gradient 3, 0 min. 20%B then 20% to 100% over 15 min.). Fractions were analysed by analytical Hplc and MALDI-TOF before pooling those with >95% purity for lyophilisation.

**Analysis:** Analytical Hplc was on a Shimadzu LC6 gradient system equipped with an autosampler, a variable wavelength detector at flow rates of 0.4 ml/min. Eluents A and B as for preparative Hplc. Columns used were Techogell5 C18 (2x150mm) (Hplc Technology), Magellan C8 column (2.1x150 mm, 5 $\mu$ m particle size) (Phenomenex)) Purified products were further analysed by MALDI-TOF and nmr.

## Synthesis of inhibitors

Method 1: Using a solid phase strategy on a Protein Technologies, Symphony Multiple Peptide Synthesiser by attachment of bis amino compounds to Peg-trityl chloride resin: Trityl chloride resin was typically treated with greater than 2 fold excess of the di-amine in dry DCM. The resin was further modified by the attachment of acids. Activation of Fmoc protected amino acid (2-5eq) was by TBTU/ DIPEA, all couplings ( minimum 120 min.) were carried out in DMF. Deprotection of the Fmoc group was achieved with 20% piperidine in DMF. In the next stage other acid substituents were added as the HOBT or HOAt esters either by activation with HBTU/HATU or HATU/EDCI with or without Boc protection of amino groups. Cleavage of the products from the resin was by treatment (30 min., ambient) with 10% triethylsilane in TFA, filtration, evaporation and trituration with diethylether.

20

Synthesis using the Symphony Multiple Peptide Synthesiser.

The Symphony Multiple Peptide Synthesiser is charged with DMF, DCM, TBTU in DMF (450 mM), DIPEA in DMF (900 mM), 20% piperidine in DMF. Resins are held in plastic reaction vessels that allow the introduction of reagents and solvents and nitrogen for agitation or air drying.

30

A typical synthesis cycle on the Symphony is as follows:-

35

The reaction vessel containing the resin (0.1 mmol) is charged with the Fmoc protected amino acid (0.5 mmol) and then this is dissolved in DMF (2.5ml), treated with TBTU (0.56 mmol, 1.25ml) and DIPEA (1.1 mmol, 1.25ml) and agitated with nitrogen for 2 hours (agitation times

may vary). After coupling the resin is washed with DMF (6x 5ml) then deprotected with 20% piperidine in DMF (2x 5ml for 1 min.each, then 1x 5ml for 8 min.) the resin is then washed with DMF (6x 5ml).

5

**Example 1.**

**2-Amino-4-chlorobenzoyl-D-phenylglycine**

**4,4'bispiperidinamide**

10 4,4-Bipiperidine.dihydrochloride (4mmol,1g) was dissolved in water (5ml) and 2M sodium hydroxide solution (10mmol, 5ml) added. The solution was extracted with ethylacetate (2x 50ml) the combined extracts were washed with water, dried over anhydrous sodium  
15 carbonate, filtered and evaporated to give the 4,4 bipiperidine (0.35g) as a white solid. The 4,4 bipiperidine was dissolved in dry DMF (2ml) and added to Peg-tritylchloride resin (0.95 mmol/g, 1.5g) pre swollen in dry DCM (10ml). After 2h the resin was washed with  
20 DCM (6x5ml), DMF (6x5ml) and DCM (6x5ml). The resin was then air dried to allow aliquots to be taken.

The 4,4 bipiperidine trityl resin (0.1 mmol) was treated with Fmoc-D-Phenylglycine (0.5 mmol, 187mg),  
25 DMF(2.5ml), TBTU in DMF(1.25ml of a 450mM solution) and DIPEA in DMF (1.25ml of a 900 mM solution). The mixture was agitated with nitrogen for 2 hours. Deprotection and washing as above.

30 A solution of 4-chloroanthranilic acid (87mg 0.5mmole) in dry dimethylformamide (DMF) was treated successively with HOAt (102mg 0.75mmole) and EDCI (115mg 0.6mmole) and stirred at room temperature for 10min. The mixture was transferred to the reaction vessel on the Symphony  
35 and agitated for 2 hours with nitrogen. The resin was washed with DMF (6x5ml), DCM (6x5ml) and air dried. The product was cleaved from the resin with 10%



triethylsilane in TFA (10ml) for 30 minutes, the resin filtered off and the TFA solution evaporated to dryness and triturated with diethyl ether to give the crude product. The crude product was dissolved in water (10ml), filtered and purified by preparative reverse phase Hplc.

<sup>1</sup>H nmr (CD<sub>3</sub>CN) 7.30 (6H,m); 6.60 (1H,s); 6.55 (1H,d); 5.85 (1H, s); 4.40 (1H,m); 3.75 (1H, m); 2.30-2.95 (6H, m); 1.60 (4H, m); 1.10 (6H, m) MS TOF 456 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt 11.77 min.

**Example 2.**

**2-Amino-5-bromobenzoyl-D-phenylglycine  
4,4'bispiperidinamide**

<sup>1</sup>H nmr (CD<sub>3</sub>CN) 7.30 (7H,m); 6.50 (1H,d); 5.85 (1H, s); 4.40 (1H,m); 3.75 (1H, m); 2.30-2.95 (6H, m); 1.60 (4H, m); 1.10 (6H, m) MS TOF 500 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt 11.31 min.

**Example 3.**

**2-Amino-4-methylbenzoyl-D-phenylglycine  
4,4'bispiperidinamide**

<sup>1</sup>H nmr (CD<sub>3</sub>CN) 7.30 (6H,m); 6.50 (1H,s); 6.45 (1H,d); 5.80 (1H, s); 4.40 (1H,m); 3.75 (1H, m); 2.30-2.95 (6H, m); 2.05 (3H,s); 1.60 (4H, m); 1.10 (6H, m) MS TOF 436 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt 9.22 min.

**Example 4.**

**2-Amino-5-methylbenzoyl-D-phenylglycine  
4,4'bispiperidinamide**

<sup>1</sup>H nmr (CD<sub>3</sub>CN) 7.30 (7H,m); 6.50 (1H,d); 5.85 (1H, s); 4.40 (1H,m); 3.75 (1H, m); 2.30-2.95 (6H, m); 1.60 (4H, m); 1.10 (6H, m). MS TOF 436 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt 8.74 min.

**Example 5.**

**2-Amino-5-methoxybenzoyl-D-phenylglycine**

**4,4'bispiperidinamide**

<sup>1</sup>H nmr (CD<sub>3</sub>CN) 7.55 (6H,m); 7.30 (1H,d); 6.95 (1H,m);  
6.15 (1H, s); 4.40 (1H,m); 3.75 (1H, m); 3.60 (3H, s);  
2.30-2.95 (6H, m); 2.20 (3H, s); 1.60 (4H, m); 1.10 (6H,  
5 m) MS TOF 452 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3,  
water/acetonitrile/TFA) rt 8.20 min.

**Example 6.**

**2-Dimethylaminobenzoyl-D-phenylglycine**

**4,4'bispiperidinamide**

10 <sup>1</sup>H nmr (CD<sub>3</sub>CN) 7.80 (1H,d); 7.65 (2H,m); 7.30 (6H,m);  
5.85 (1H, s); 4.40 (1H,m); 3.75 (1H, m); 3.10 (6H, s);  
2.30-2.95 (6H, m); 1.60 (4H, m); 1.10 (6H, m) MS TOF 450  
(M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3,  
water/acetonitrile/TFA) rt 9.57 min.

**Example 7.**

**3-Methylbenzoyl-D-phenylglycine 4,4'bispiperidinamide**

<sup>1</sup>H nmr (CD<sub>3</sub>CN) 7.40 (2H,m); 7.30 (7H,m); 5.85 (1H, s);  
4.40 (1H,m); 3.75 (1H, m); 2.30-2.95 (6H, m); 2.20 (3H,  
s); 1.60 (4H, m); 1.10 (6H, m) MS TOF 421 (M+1<sup>+</sup>). Hplc  
20 (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt  
10.68 min.

**Example 8.**

**4-Methylbenzoyl-D-phenylglycine 4,4'bispiperidinamide**

<sup>1</sup>H nmr (CD<sub>3</sub>CN) 7.55 (2H,m); 7.30 (5H,m); 7.10 (2H,m);  
25 5.85 (1H, s); 4.40 (1H,m); 3.75 (1H, m); 2.30-2.95 (6H,  
m); 2.20 (3H,s); 1.60 (4H, m); 1.10 (6H, m) MS TOF 420  
(M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3,  
water/acetonitrile/TFA) rt 10.61 min.

**Example 9.**

**3-Amino-2-naphthoyl-D-phenylglycine**

**4,4'bispiperidinamide**

<sup>1</sup>H nmr (CD<sub>3</sub>CN) 7.90 (1H,d); 7.60 (1H,d); 7.40 (1H,m);  
7.30 (6H,m); 7.05 (1H,m); 6.90 (1H,s); 5.85 (1H, s);  
4.40 (1H,m); 3.75 (1H, m); 2.30-2.95 (6H, m); 1.60 (4H,  
35 m); 1.10 (6H, m) MS TOF 471 (M+1<sup>+</sup>). Hplc (Magellan C8,  
Gradient 3, water/acetonitrile/TFA) rt 9.87 min.

**Example 10.**

3-Aminobenzoyl-D-phenylglycine 4,4'bispiperidinamide  
MS TOF 421 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3,  
water/acetonitrile/TFA) rt 9.06 min.

Example 11.

5 2-Aminobenzoyl-D-phenylglycine 4,4'bispiperidinamide  
MS TOF 421 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3,  
water/acetonitrile/TFA) rt 9.00 min.

Example 12.

2-Amino-4-fluorobenzoyl-D-phenylglycine  
10 4,4'bispiperidinamide  
MS TOF 440 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3,  
water/acetonitrile/TFA) rt 9.23 min.

Example 13.

2-Amino-5-fluorobenzoyl-D-phenylglycine  
15 4,4'bispiperidinamide  
MS TOF 440 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3,  
water/acetonitrile/TFA) rt 9.14 min.

Example 14.

2-Amino-4-nitrobenzoyl-D-phenylglycine  
20 4,4'bispiperidinamide  
MS TOF 467 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3,  
water/acetonitrile/TFA) rt 10.59 min.

Example 15.

2-Amino-5-nitrobenzoyl-D-phenylglycine  
25 4,4'bispiperidinamide  
MS TOF (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3,  
water/acetonitrile/TFA) rt 10.57 min.

Example 16.

2-Amino-4,5-dimethoxybenzoyl-D-phenylglycine  
30 4,4'bispiperidinamide  
MS TOF 481 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3,  
water/acetonitrile/TFA) rt 11.67 min.

Example 17.

Benzoyl-D-phenylglycine 4,4'bispiperidinamide  
35 MS TOF 407 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3,  
water/acetonitrile/TFA) rt 9.88 min.

Example 18.

**4-Chlorobenzoyl-D-phenylglycine 4,4'bispiperidinamide**  
MS TOF 441 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3,  
water/acetonitrile/TFA) rt 10.89 min.

**Example 19.**

5     **2-Hydroxybenzoyl-D-phenylglycine 4,4'bispiperidinamide**  
MS TOF 423 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3,  
water/acetonitrile/TFA) rt 8.97 min.

**Method 2:** By solution phase strategy: Typically an  
10     activated Boc-amino acid was treated with an amine  
(primary or secondary) or alcohol (1eq.). Activation of  
Boc protected amino acid was by HATU or TBTU/  
DIPEA(1:2), all couplings (minimum 120 min.) were  
carried out in DMF. After an aqueous work up the  
15     deprotection of the Boc group was achieved with TFA.  
Other acid substituents were added as the HOBt or HOAt  
esters either by activation with HBTU/HATU, EDC or DIPCI  
with or without Boc protection of amino groups. The  
final products were purified by preparative reverse  
20     phase Hplc.

**Example 20.**

**3-Hydroxymethylbenzoyl-D-phenylglycine-4-  
methylbenzylamide**

25     Boc D-phenylglycine (251 mg, 1 mmol.) was dissolved in  
DMF(3ml) with HATU (380 mg., 1 mmol.) and DIPEA(350 $\mu$ l.,  
2 mmol.). To this mixture was added 4-  
methylbenzylamine(121mg., 1 mmol.) and DIPEA (170 $\mu$ l., 1  
mmol.). The mixture was stirred overnight. The mixture  
30     was then taken up into ethylacetate and washed with  
water, sodium carbonate solution, water, 10%  
hydrochloric acid solution and water. The ethylacetate  
was evaporated without drying and treated immediately  
with TFA for 30 min. The TFA was then evaporated to  
35     dryness and the product triturated with diethylether.  
TEA(1ml) was added and evaporated to dryness. A solution  
of 3-hydroxymethylbenzoic acid (76mg, 0.5mmole) in dry

dimethylformamide (DMF) was treated with TBTU (161mg.,  
0.5mmol.) and DIPEA (1.5 mmol.). The mixture was then  
added to the D-phenylglycine-4-methylbenzylamide  
(0.5mmol.) and stirred overnight. The crude product was  
5 dissolved in water/acetonitrile (20ml), filtered and  
purified by preparative Hplc to yield pure product.

<sup>1</sup>H nmr (CD<sub>3</sub>CN) 7.75 (1H, m); 7.65 (2H, m); 7.30 (7H,  
broad m); 6.80 (3H, m); 5.40 (1H, s); 4.45 (2H,s); 4.10  
10 (2H, m); 2.10 (3H, s). MS TOF 389 (M+1<sup>+</sup>). Hplc (Magellan  
C8, Gradient 3, water/acetonitrile/TFA) rt 13.51 min.

Compounds made by the above method:-

15 **Example 21.**

**3-Hydroxybenzoyl-D-phenylglycine-4-methylbenzylamide**

<sup>1</sup>H nmr (CD<sub>3</sub>CN) 7.75 (1H, m); 7.40 (2H, m); 7.30 (5H,  
broad m); 6.95 (5H, m); 5.40 (1H, s); 4.20 (2H, m); 2.20  
(3H, s). MS TOF 375 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient  
20 3, water/acetonitrile/TFA) rt 12.28 min.

**Example 22.**

**3-Aminobenzoyl-D-phenylglycine-4-methylbenzylamide**

<sup>1</sup>H nmr (CD<sub>3</sub>CN) 7.70-7.30 (13H, broad m); 5.65 (1H, s);  
4.35 (2H, m); 2.25 (3H, s). MS TOF 374 (M+1<sup>+</sup>). Hplc  
25 (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt  
10.44 min.

**Example 23.**

**3-Amidobenzoyl-D-phenylglycine-4-methylbenzylamide**

<sup>1</sup>H nmr (CD<sub>3</sub>CN) 8.40 (1H, m); 8.20 (2H, m); 7.60 (6H,  
30 broad m); 7.20 (4H, m); 5.75 (1H, s); 4.50 (2H, m); 2.40  
(3H, s). MS TOF 402 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient  
3, water/acetonitrile/TFA) rt 11.16 min.

**Example 24.**

**3-Aminomethylbenzoyl-D-phenylglycine-4-methylbenzylamide**

35 <sup>1</sup>H nmr (CD<sub>3</sub>CN) 7.80 (2H, m); 7.45 (5H, m); 7.30 (2H, m);  
6.95 (4H, m); 5.55 (1H, s); 4.25 (2H,s); 4.05 (2H, s);  
2.20 (3H, s). MS TOF 388 (M+1<sup>+</sup>). Hplc (Magellan C8,

Gradient 3, water/acetonitrile/TFA) rt 12.28 min.

**Example 25.**

**3-Amidobenzoyl-D-phenylglycine-4-(aminomethyl)benzylamide**

5 <sup>1</sup>H nmr (CD<sub>3</sub>CN) 8.20 (1H, s); 7.95 (2H, m); 7.60 (1H, m); 7.30 (5H, broad m); 6.95 (5H, m); 5.40 (1H, s); 4.20 (2H, m); 2.20 (3H, s). MS TOF 417 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 2, water/acetonitrile/TFA) rt 14.05 min.

**Example 26.**

10 **3-Aminomethylbenzoyl-D-phenylglycine-4-aminomethylcyclohexyl methylamide**

<sup>1</sup>H nmr (CD<sub>3</sub>CN) 7.95 (2H, m); 7.80 (2H, m); 7.50 (5H, m); 5.65 (1H, s); 4.45 (2H, s); 3.30 (2H, m); 3.00 (2H, m); 2.00-1.00 (10H, m). MS TOF 409 (M+1<sup>+</sup>). Hplc (Magellan C8, 15 Gradient 3, water/acetonitrile/TFA) rt 12.68 min.

**Example 27.**

**2-Amino-N-[1-(ethoxycarbonyl)-1-(phenyl)methyl]benzimidazole-5-carboxamide**

<sup>1</sup>H nmr (CD<sub>3</sub>CN) 7.80 (1H, s); 7.55 (1H, d); 7.40 (5H, m); 20 7.20 (1H, d); 5.85 (1H, s); 4.15 (2H, m); 1.25 (3H, m). MS TOF 339 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 2, water/acetonitrile/TFA) rt 17.05 min.

**Example 28.**

**3-Aminomethylbenzoyl-D-phenylglycine-1-adamantylamide**

25 <sup>1</sup>H nmr (CD<sub>3</sub>CN) 7.95 (1H, s); 7.85 (2H, d); 7.60 (1H, m); 7.50 (2H, m); 7.40 (3H, m); 5.65 (1H, s); 4.20 (2H, s); 2.50-1.50 (15H, m). MS TOF 418 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 1, water/acetonitrile/TFA) rt 18.36 min.

**Example 29.**

30 **2-Aminobenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide**

<sup>1</sup>H nmr (DMSO) 7.65 (3H, m); 7.45 (1H, m); 7.35 (5H, m); 7.15 (1H, m); 6.65 (1H, d); 6.55 (1H, m); 6.05 (1H, s); 3.15 (3H, s); 3.00-2.00 (8H, m). MS TOF 511 (M+1<sup>+</sup>). Hplc 35 (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt 13.43 min.

**Example 30.**

**2-Amino-4-chlorobenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide**

<sup>1</sup>H nmr (DMSO) 7.55 (3H, m); 7.45 (1H, m); 7.35 (5H, m); 7.15 (1H, m); 6.75 (1H, s); 6.55 (1H, d); 6.05 (1H, s); 3.15 (3H, s); 3.00-2.00 (8H, m). MS TOF 546 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt 15.18 min.

**Example 31.**

**2-Amino-5-fluorobenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide**

<sup>1</sup>H nmr (CDCl<sub>3</sub>) 7.75 (1H, m); 7.60 (1H, m); 7.25 (6H, m); 7.15 (1H, m); 6.90 (1H, m); 6.75 (1H, m); 5.85 (1H, s); 3.15 (3H, s); 3.00-2.00 (8H, m). MS TOF 529 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt 13.87 min.

**Example 32.**

**2-Amino-4-methylbenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide**

<sup>1</sup>H nmr (DMSO) 7.55 (3H, m); 7.45 (2H, m); 7.35 (5H, m); 6.65 (1H, s); 6.35 (1H, d); 6.05 (1H, s); 3.15 (3H, s); 3.00-2.00 (8H, m) 2.15 (3H, s);. MS TOF 525 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt 13.12 min.

**Example 33.**

**2-Amino-5-methylbenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide**

<sup>1</sup>H nmr (CDCl<sub>3</sub>) 7.75 (1H, m); 7.60 (1H, m); 7.25 (6H, m); 7.15 (1H, m); 6.90 (1H, m); 6.75 (1H, m); 5.85 (1H, s); 3.15 (3H, s); 3.00-2.00 (8H, m) 2.30 (3H, s). MS TOF 525 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt 12.84 min.

**Example 34.**

**2-Amino-4-nitrobenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide**

<sup>1</sup>H nmr (CDCl<sub>3</sub>) 7.75 (2H, m); 7.55 (1H, m); 7.35 (7H, m); 7.25 (1H, m); 5.80 (1H, s); 3.15 (3H, s); 3.00-2.00 (8H, m). MS TOF 556 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient

3, water/acetonitrile/TFA) rt 15.35 min.

**Example 35.**

**2-Amino-5-nitrobenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide**

5 <sup>1</sup>H nmr (CDCl<sub>3</sub>) 8.25 (1H, d); 7.85 (1H, m); 7.55 (1H, m);  
7.25 (7H, m); 7.05 (1H, m); 5.80 (1H, s); 3.15 (3H, s);  
3.00-2.00 (8H, m). MS TOF 556 (M+1<sup>+</sup>). Hplc (Magellan C8,  
Gradient 3, water/acetonitrile/TFA) rt 15.08 min.

**Example 36.**

10 **2-Amino-5-cyanobenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide**

<sup>1</sup>H nmr (CD<sub>3</sub>CN) 7.65 (4H, m); 7.25 (6H, m); 6.65 (1H, d);  
5.80 (1H, s); 3.15 (3H, s); 3.00-2.00 (8H, m). MS TOF 536  
15 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3,  
water/acetonitrile/TFA) rt 14.89 min.

**Example 37.**

**2,5-Diaminobenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide**

<sup>1</sup>H nmr (CDCl<sub>3</sub>) 7.70 (1H, d); 7.45 (7H, m); 6.85 (1H, s);  
20 6.55 (1H, m); 6.55 (1H, m); 5.90 (1H, s); 3.15 (3H, s);  
3.00-2.00 (8H, m). MS TOF 526 (M+1<sup>+</sup>). Hplc (Magellan C8,  
Gradient 3, water/acetonitrile/TFA) rt 11.82 min.

**Example 38.**

25 **2-Amino-4,5-dimethoxybenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide**

<sup>1</sup>H nmr (CD<sub>3</sub>CN) 7.65 (2H, m); 7.35 (2H, m); 7.25 (5H, m);  
6.75 (1H, d); 6.15 (1H, d); 5.80 (1H, s); 3.60 (3H, s);  
3.50 (3H, s); 3.15 (3H, s); 3.00-2.00 (8H, m). MS TOF 571  
30 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3,  
water/acetonitrile/TFA) rt 12.84 min.

**Example 39.**

**Benzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide**

<sup>1</sup>H nmr (CD<sub>3</sub>CN) 7.75 (2H, m); 7.70 (1H, m); 7.40 (10H, m);  
35 6.05 (1H, s); 3.15 (3H, s); 3.00-2.00 (8H, m). MS TOF 496  
(M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3,  
water/acetonitrile/TFA) rt 12.84 min.



Example 40.

2-Methylaminobenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide

<sup>1</sup>H nmr (CD<sub>3</sub>CN) 7.75 (1H, m); 7.65 (1H, d); 7.50 (1H, d);  
5 7.45 (2H, m); 7.30 (5H, m); 6.80 (1H, d); 6.70 (1H, m);  
6.00 (1H, s); 3.15 (3H,s); 2.80 (3H,s); 3.00-2.00  
(8H,m). MS TOF 525 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient  
3, water/acetonitrile/TFA) rt 14.63 min.

Example 41.

10 2-Dimethylaminobenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide

<sup>1</sup>H nmr (CD<sub>3</sub>CN) 7.85 (1H, d); 7.50 (2H, m); 7.45 (3H, m);  
7.30 (6H, m); 6.00 (1H, s); 3.15 (3H,s); 2.80 (6H,s);  
3.00-2.00 (8H,m). MS TOF 539 (M+1<sup>+</sup>). Hplc (Magellan C8,  
15 Gradient 3, water/acetonitrile/TFA) rt 12.58 min.

Example 42.

3-Aminobenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide

<sup>1</sup>H nmr (CD<sub>3</sub>CN) 7.85 (1H, m); 7.60 (1H, m); 7.50 (2H, m);  
20 7.30 (7H, m); 7.05 (1H, d); 6.05 (1H, s); 3.15 (3H,s);  
3.00-2.00 (8H,m). MS TOF 511 (M+1<sup>+</sup>). Hplc (Magellan C8,  
Gradient 3, water/acetonitrile/TFA) rt 11.32 min.

Example 43.

25 4-Aminobenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide

<sup>1</sup>H nmr (CDCl<sub>3</sub>) 7.95 (1H, d); 7.80-7.45 (10H, broad m);  
7.35 (1H,d); 6.20 (1H, s); 3.15 (3H,s); 3.00-2.00  
(8H,m). MS TOF 511 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient  
3, water/acetonitrile/TFA) rt 12.05 min.

30 Example 44..

3,4 Diaminobenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide

<sup>1</sup>H nmr (CDCl<sub>3</sub>) 7.75 (1H, d); 7.40-7.15 (9H, broad m);  
6.55 (1H,d); 6.00 (1H, s); 3.15 (3H,s); 3.00-2.00  
35 (8H,m). MS TOF 540 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient  
3, water/acetonitrile/TFA) rt 11.30 min.

Example 45.

**3-Chlorobenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide**

<sup>1</sup>H nmr (CD<sub>3</sub>CN) 7.85 (1H, m); 7.80 (1H, s); 7.60 (2H, m); 7.30 (8H, m); 6.00 (1H, s); 3.20 (3H,s); 3.00-2.00 (8H,m). MS TOF 531 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt 15.40 min.

**Example 46.**

**4-Chlorobenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide**

<sup>1</sup>H nmr (CD<sub>3</sub>CN) 7.95 (1H, m); 7.75 (2H, m); 7.60 (1H, m); 7.40 (8H, m); 6.05 (1H, s); 3.25 (3H,s); 3.00-2.00 (8H,m). MS TOF 531 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt 16.54 min.

**Example 47.**

**3-Amino-4-chlorobenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide**

<sup>1</sup>H nmr (CDCl<sub>3</sub>) 8.05 (1H, m); 7.80 (1H, m); 7.70 (1H, s); 7.20-7.60 (8H, broad m); 6.05 (1H, s); 3.25 (3H,s); 3.00-2.00 (8H,m). MS TOF 546 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt 14.53 min.

**Example 48.**

**4-Bromobenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide**

<sup>1</sup>H nmr (CD<sub>3</sub>CN) 7.85 (1H, m); 7.65 (2H, m); 7.60 (2H, d); 7.45 (2H, d); 7.30 (5H, m); 6.00 (1H, s); 3.20 (3H,s); 3.00-2.00 (8H,m). MS TOF 576 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt 15.94 min.

**Example 49.**

**4-Iodobenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide**

<sup>1</sup>H nmr (CD<sub>3</sub>CN)) 7.75 (2H, m); 7.65 (1H, m 7.55 (2H, d); 7.45 (2H, d); 7.30 (5H, m); 5.95 (1H, s); 3.20 (3H,s); 3.00-2.00 (8H,m). MS TOF 622 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt 15.96 min.

**Example 50.**

**3-Amino-4-methylbenzoyl-D-phenylglycine-N-(4-fluoro-2-**

**methylsulphonylphenyl)piperazinamide**

<sup>1</sup>H nmr (CDCl<sub>3</sub>) 7.95 (1H, s); 7.60 (1H, d); 7.45 (1H, d);  
7.40-7.15 (8H, broad m); 6.00 (1H, s); 3.15 (3H, s);  
3.00-2.50 (8H, m) 2.20 (3H, s). MS TOF 525 (M+1<sup>+</sup>). Hplc  
5 (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt  
11.71 min.

**Example 51.**

**4-Methoxybenzoyl-D-phenylglycine-N-(4-fluoro-2-  
methylsulphonylphenyl)piperazinamide**

10 <sup>1</sup>H nmr (CD<sub>3</sub>CN) 7.85 (2H, d); 7.65 (1H, m); 7.50 (2H, m);  
7.40 (5H, m); 6.80 (2H, d); 6.00 (1H, s); 3.80 (3H, s);  
3.20 (3H, s); 3.00-2.00 (8H, m). MS TOF 526 (M+1<sup>+</sup>). Hplc  
(Magellan C8, Gradient 3, water/acetonitrile/TFA) rt  
14.63 min.

15 **Example 52.**

**3-Amino-4-methoxybenzoyl-D-phenylglycine-N-(4-fluoro-2-  
methylsulphonylphenyl)piperazinamide**

<sup>1</sup>H nmr (CDCl<sub>3</sub>) 7.90 (1H, m); 7.75 (1H, d); 7.60 (2H, m);  
7.40-7.15 (6H, broad m); 7.45 (1H, d); 6.10 (1H, s);  
20 3.95 (3H, s); 3.35 (3H, s); 3.00-2.50 (8H, m). MS TOF 541  
(M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3,  
water/acetonitrile/TFA) rt 11.78 min.

**Example 53.**

25 **3,4-Dihydroxybenzoyl-D-phenylglycine-N-(4-fluoro-2-  
methylsulphonylphenyl)piperazinamide**

<sup>1</sup>H nmr (CDCl<sub>3</sub>) 7.55 (1H, m); 7.45 (1H, d); 7.25 (2H, m);  
7.15 (5H, m); 7.00 (1H, d); 6.60 (1H, d); 5.80 (1H, s);  
3.05 (3H, s); 3.00-2.50 (8H, m). MS TOF 541 (M+1<sup>+</sup>). Hplc  
(Magellan C8, Gradient 3, water/acetonitrile/TFA) rt  
30 11.78 min.

**Example 54.**

**Naphth-2-oyl-D-phenylglycine-N-(4-fluoro-2-  
methylsulphonylphenyl)piperazinamide**

<sup>1</sup>H nmr (CDCl<sub>3</sub>) 8.35 (1H, s); 8.00 (1H, d); 7.85 (5H, m);  
35 7.45 (4H, m); 7.25 (4H, m); 6.10 (1H, s); 3.20 (3H, s);  
3.00-2.50 (8H, m). MS TOF 546 (M+1<sup>+</sup>). Hplc (Magellan C8,  
Gradient 3, water/acetonitrile/TFA) rt 16.66 min.

**Example 55.**

**3-Aminonaphth-2-oyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide**

<sup>1</sup>H nmr (CDCl<sub>3</sub>) 8.15 (1H, d); 8.00 (1H, s); 7.75 (2H, m);  
5 7.65 (1H, d); 7.30 7.60 (9H, m); 6.10 (1H, s); 3.25  
(3H, s); 3.00-2.50 (8H, m). MS TOF 561 (M+1<sup>+</sup>). Hplc  
(Magellan C8, Gradient 3, water/acetonitrile/TFA) rt  
13.90 min.

**Example 56.**

10 **Thiophene-3-oyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide**

<sup>1</sup>H nmr (CDCl<sub>3</sub>) 8.15 (1H, s); 7.95 (1H, m); 7.85 (1H, m);  
7.60 (8H, m); 6.30 (1H, s); 3.45 (3H, s); 2.00-2.50  
(8H, m). MS TOF 502 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient  
15 3, water/acetonitrile/TFA) rt 14.28 min.

**Example 57.**

**Thiophene-2-oyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide**

<sup>1</sup>H nmr (CDCl<sub>3</sub>) 7.65 (2H, m); 7.45 (1H, s); 7.30 (2H, m);  
20 7.20 (5H, m); 6.95 (1H, m); 6.00 (1H, s); 3.05 (3H, s);  
3.00-2.50 (8H, m). MS TOF 502 (M+1<sup>+</sup>). Hplc (Magellan C8,  
Gradient 3, water/acetonitrile/TFA) rt 14.52 min.

**Example 58.**

25 **5-Methyl thiophene-2-oyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide**

<sup>1</sup>H nmr (CDCl<sub>3</sub>) 7.70 (1H, m); 7.45 (2H, m); 7.35 (6H, m);  
6.65 (1H, m); 6.00 (1H, s); 3.05 (3H, s); 3.00-2.50  
(8H, m) 2.45 (3H, s). MS TOF 516 (M+1<sup>+</sup>). Hplc (Magellan  
C8, Gradient 3, water/acetonitrile/TFA) rt 14.98 min.

30 **Example 59.**

**Isoquinolin-7-oyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide**

<sup>1</sup>H nmr (CD<sub>3</sub>CN) 9.50 (1H, s); 8.75 (1H, s); 8.55 (1H, d);  
8.30 (1H, d); 8.10 (2H, m); 7.65 (1H, m); 7.45 (2H, m);  
35 7.35 (5H, m); 6.10 (1H, s); 3.20 (3H, s); 3.00-2.50  
(8H, m). MS TOF 547 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient  
3, water/acetonitrile/TFA) rt 11.39 min.

**Example 60.**

**Pyridin-3-oyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide**

<sup>1</sup>H nmr (CD<sub>3</sub>CN) 9.00 (1H, s); 8.70 (1H, d); 8.35 (1H, d);  
5 8.10 (1H, m); 7.65 (2H, m); 7.45 (1H, m); 7.30 (5H, m);  
6.00 (1H, s); 3.20 (3H, s); 3.00-2.50 (8H, m). MS TOF 497  
(M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3,  
water/acetonitrile/TFA) rt 11.99 min.

**Example 61.**

10 **Indol-6-oyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide**

<sup>1</sup>H nmr (CD<sub>3</sub>CN) 7.95 (2H, m); 7.60 (2H, m); 7.50 (3H, m);  
7.35 (5H, m); 6.45 (1H, s); 6.05 (1H, s); 3.25 (3H, s);  
3.00-2.50 (8H, m). MS TOF 535 (M+1<sup>+</sup>). Hplc (Magellan C8,  
15 Gradient 3, water/acetonitrile/TFA) rt 15.44 min.

**Example 62.**

**2,4-Diaminobenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide**

MS TOF 526 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3,  
20 water/acetonitrile/TFA) rt 11.89 min.

**Example 63.**

**4-Methylaminobenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide**

<sup>1</sup>H nmr (CD<sub>3</sub>CN) 7.65 (3H, m); 7.50 (2H, m); 7.35 (5H, m);  
25 6.60 (2H, d); 6.05 (1H, s); 3.30 (3H, s); 3.00-2.50  
(8H, m); 2.80 (3H, s). MS TOF 525 (M+1<sup>+</sup>). Hplc (Magellan  
C8, Gradient 3, water/acetonitrile/TFA) rt 13.17 min.

**Example 64.**

30 **3-Methyl-4-chlorobenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide**

<sup>1</sup>H nmr (CD<sub>3</sub>CN) 7.90 (1H, s); 7.85 (1H, s); 7.80 (1H, s);  
7.55 (6H, m); 6.25 (1H, s); 3.45 (3H, s); 3.00-2.50  
(8H, m); 2.60 (3H, s). MS TOF 545 (M+1<sup>+</sup>). Hplc (Magellan  
C8, Gradient 3, water/acetonitrile/TFA) rt 16.39 min.

35 **Example 65.**

**4-Vinylbenzoyl-D-phenylglycine-N-(4-fluoro-2-methylsulphonylphenyl)piperazinamide**

<sup>1</sup>H nmr (CD<sub>3</sub>CN) 7.75 (2H, d); 7.60 (1H, m); 7.45 (4H, m);  
7.35 (5H, m); 6.75 (1H, m); 6.05 (1H, s); 5.90 (1H, d);  
5.30 (1H, d); 3.00-2.50 (8H, m); 2.80 (3H, s). MS TOF  
522 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3,  
5 water/acetonitrile/TFA) rt 15.45 min.

**Example 66.**

**3-Amino-4-hydroxybenzoyl-D-phenylglycine-N-(4-fluoro-2-methyl sulphonylphenyl)piperazinamide**

<sup>1</sup>H nmr (CD<sub>3</sub>CN) 7.60 (1H, m); 7.50-7.10 (9H, m); 7.35  
10 (1H, d); 5.95 (1H, s); 3.25 (3H, s); 3.00-2.50 (8H, m).  
MS TOF 527 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 2,  
water/acetonitrile/TFA) rt 15.46 min.

**Example 67.**

**4-Methylthiobenzoyl-D-phenylglycine-N-(4-fluoro-2-methyl  
15 sulphonylphenyl)piperazinamide**

<sup>1</sup>H nmr (CD<sub>3</sub>CN) 7.85 (2H, d); 7.80 (1H, m); 7.60 (2H, m);  
7.50 (5H, m); 7.40 (2H, d); 6.15 (1H, s); 3.40 (3H, s);  
3.10-2.70 (8H, m); 2.60 (3H, s). MS TOF 542 (M+1<sup>+</sup>). Hplc  
(Magellan C8, Gradient 3, water/acetonitrile/TFA) rt  
20 16.67 min.

**Example 68.**

**3 Carboxamidobenzoyl-D-phenylglycine-N-(4-fluoro-2-methyl sulphonylphenyl)piperazinamide**

<sup>1</sup>H nmr (CD<sub>3</sub>CN) 8.25 (1H, s); 7.95 (2H, d); 7.70 (1H, m);  
25 7.55 (3H, m); 7.40 (5H, m); 6.05 (1H, s); 3.30 (3H,  
s); 3.00-2.50 (8H, m). MS TOF 539 (M+1<sup>+</sup>). Hplc (Magellan  
C8, Gradient 3, water/acetonitrile/TFA) rt 12.83 min.

**Example 69.**

**3-Amino-4-methylcarboxybenzoyl-D-phenylglycine-N-(4-  
30 fluoro-2-methyl sulphonylphenyl)piperazinamide**

<sup>1</sup>H nmr (CD<sub>3</sub>CN) 7.90 (1H, d); 7.70 (1H, m); 7.55 (2H, m);  
7.45 (5H, m); 7.20 (1H, s); 6.95 (1H, d); 6.05 (1H, s);  
3.80 (3H, s); 3.30 (3H, s); 3.00-2.50 (8H, m). MS TOF  
569 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3,  
35 water/acetonitrile/TFA) rt 14.49 min.

**Example 70.**

**3-Methyl-4-bromobenzoyl-D-phenylglycine-N-(4-fluoro-2-**

**methyl sulphonylphenyl)piperazinamide**

<sup>1</sup>H nmr (CD<sub>3</sub>CN) 7.65 (3H, m); 7.45 (3H, m); 7.30 (5H, m);  
6.00 (1H, s); 3.25 (3H, s); 3.00-2.50 (8H, m); 2.40  
(3H, s). MS TOF 589 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient  
5 3, water/acetonitrile/TFA) rt 16.67 min.

**Example 71.**

**4-Ethoxybenzoyl-D-phenylglycine-N-(4-fluoro-2-methyl  
sulphonylphenyl)piperazinamide**

<sup>1</sup>H nmr (CD<sub>3</sub>CN) 7.75 (2H, d); 7.60 (1H, m); 7.50 (2H, m);  
10 7.35 (5H, m); 6.85 (2H, d); 6.00 (1H, s); 4.00 (2H,  
m); 3.20 (3H, s); 3.00-2.50 (8H, m); 1.30 (3H, t). MS  
TOF 540 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3,  
water/acetonitrile/TFA) rt 16.58 min.

**Example 72.**

15 **5-Indoloyl-D-phenylglycine-N-(4-fluoro-2-methyl  
sulphonylphenyl)piperazinamide**

<sup>1</sup>H nmr (CD<sub>3</sub>CN) 8.15 (1H, s); 7.95 (1H, m); 7.65 (2H, m);  
7.60-7.35 (7H, m); 6.60 (1H, s); 6.10 (1H, s); 3.30  
(3H, s); 3.00-2.60 (8H, m). MS TOF 535 (M+1<sup>+</sup>). Hplc  
20 (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt  
13.88 min.

**Example 73.**

**5-Benzamidazoyl-D-phenylglycine-N-(4-fluoro-2-methyl  
sulphonylphenyl)piperazinamide**

25 <sup>1</sup>H nmr (CD<sub>3</sub>CN) 8.75 (1H, s); 8.25 (1H, s); 7.75 (2H, m);  
7.60 (1H, m); 7.50 (2H, m); 7.35 (5H, m); 6.60 (2H, d);  
6.05 (1H, s); 3.30 (3H, s); 3.00-2.50 (8H, m). MS TOF  
536 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3,  
water/acetonitrile/TFA) rt 10.08 min.

30 **Example 74.**

**3-Aminobenzoyl-D-phenylglycine-1'-methyl-  
4,4'-bispiperidinamide**

<sup>1</sup>H nmr (CD<sub>3</sub>CN) a mixture of conformers only one recorded  
here 7.65 (1H, m); 7.35 (5H, m); 7.05 (1H, m); 6.95  
35 (2H, m); 5.85 (1H, s); 4.45 (1H, m); 3.85 (1H, m); 3.30  
(2H, m); 2.90-2.40 (8H, m); 2.55 (3H, s); 1.60 (2H, m);  
1.30 (2H, m); 1.00 (2H, m). MS TOF 435 (M+1<sup>+</sup>). Hplc

(Magellan C8, Gradient 3, water/acetonitrile/TFA) rt 7.65 min.

**Example 75.**

**3-Amino-4-chlorobenzoyl-D-phenylglycine-1'-methyl-4,4'bispiperidinamide**

<sup>1</sup>H nmr (CD<sub>3</sub>CN) a mixture of conformers only one recorded here 7.75 (1H, m); 7.30 (5H, m); 7.20 (1H, m); 6.95 (1H, m); 5.85 (1H, s); 4.45 (1H, m); 3.85 (1H, m); 3.30 (2H, m); 2.90-2.40 (8H, m); 2.55 (3H, s); 1.60 (2H, m); 1.30 (2H, m); 1.00 (2H, m). MS TOF 469 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt 9.58 min.

**Example 76.**

**3-Amino-4-methylbenzoyl-D-phenylglycine-1'-methyl-4,4'bispiperidinamide**

<sup>1</sup>H nmr (CD<sub>3</sub>CN) a mixture of conformers only one recorded here 7.75 (1H, m); 7.35 (5H, m); 7.05 (2H, m); 5.85 (1H, s); 4.45 (1H, m); 3.85 (1H, m); 3.30 (2H, m); 2.90-2.40 (8H, m); 2.65 (3H, s); 2.15 (3H, s); 1.60 (2H, m); 1.30 (2H, m); 1.00 (2H, m). MS TOF 449 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt 8.03 min

**Example 77.**

**3-Aminonaphth-2-oyl-D-phenylglycine-1'-methyl-4,4'bispiperidinamide**

<sup>1</sup>H nmr (CD<sub>3</sub>CN) a mixture of conformers only one recorded here 7.95 (1H, m); 7.65 (1H, d); 7.45 (2H, m); 7.30 (5H, m); 7.15 (1H, m); 6.95 (1H, s); 5.95 (1H, s); 4.45 (1H, m); 3.85 (1H, m); 3.30 (2H, m); 2.90-2.40 (8H, m); 2.65 (3H, s); 1.60 (2H, m); 1.30 (2H, m); 1.00 (2H, m). MS TOF 485 (M+1<sup>+</sup>). Hplc (Magellan C8, Gradient 3, water/acetonitrile/TFA) rt 9.94 min.

**Example 78.**

**Indol-6-oyl-D-phenylglycine-1'-methyl-4,4'bispiperidinamide**

<sup>1</sup>H nmr (CD<sub>3</sub>CN) a mixture of conformers only one recorded here 7.78 (2H, s); 7.50 (1H, d); 7.25 (7H, m); 6.34 (1H,



s); 6.82 (1H, s); 4.40 (1H, m); 3.83 (1H, m); 3.35 (2H, t); 2.9-2.4 (8H, m) and 2.65 (3H, s) masked by water in solvent; 1.60 (2H, m); 1.40 (2H, m); 1.08 (2H, m). MS TOF 459 (M+1<sup>+</sup>).

5 Hplc (Luna2 C18, Gradient 3, water/acetonitrile/TFA rt 10.01 min.

**Example 79.**

**3-Amino-4-fluorobenzoyl-D-phenylglycine-1'-methyl-4,4'-bispiperidinamide**

10 <sup>1</sup>H nmr (d<sub>4</sub> methanol) a mixture of conformers only one recorded here : 7.4 (6H, m); 7.1 (1H, m); 7.0 (1H, t); 6.0 (1H, s); 4.63 (1H, m); 4.02 (1H, m); 3.30 (2H, m); 2.90-2.40 (8H, m); 2.65 (3H, s); 1.60 (2H, m); 1.30 (2H, m); 1.00 (2H, m). MS TOF 453 (M+1<sup>+</sup>).

15 Hplc (Symmetry C8, Gradient 3, water/acetonitrile/TFA) rt 5.03 min.

**Example 80.**

**3-Amino-4-bromobenzoyl-D-phenylglycine-1'-methyl-4,4'-bispiperidinamide**

20 <sup>1</sup>H nmr (CD<sub>3</sub>CN) a mixture of conformers only one recorded here 7.75 (1H, m); 7.35 (5H, m); 7.05 (1H, m); 6.80 (1H, m); 5.85 (1H, s); 4.45 (1H, m); 3.85 (1H, m); 3.30 (2H, m); 2.90-2.40 (8H, m) and 2.65 (3H, s) masked by water in solvent; 1.60 (2H, m); 1.30 (2H, m); 1.00 (2H, m). MS TOF 513 and 515 (M+1<sup>+</sup>).

25 (Symmetry C8, Gradient 3, water/acetonitrile/TFA) rt 5.70 min.

**Example 81.**

**3-Amino-4-methoxybenzoyl-D-phenylglycine-1'-methyl-4,4'-bispiperidinamide**

30 <sup>1</sup>H nmr (CD<sub>3</sub>CN) a mixture of conformers only one recorded here 7.70 (1H, m); 7.30 (5H, m); 7.0 (2H, m); 6.72 (1H, d); 5.80 (1H, s); 4.45 (1H, m); 3.85 (1H, m); 3.70 (3H, s); 3.30 (2H, m); 2.9-2.4 (8H, m) masked by water in solvent; 1.60 (2H, m); 1.30 (2H, m); 1.00 (2H, m). MS TOF 465 (M+1<sup>+</sup>).

Hplc (Luna2 C18, Gradient 3, water/acetonitrile/TFA) rt

7.55 min.

**Example 82.**

**4-(Methylamino)benzoyl-D-phenylglycine-1'-methyl-4,4'-bispiperidinamide**

- 5 <sup>1</sup>H nmr (CD<sub>3</sub>CN) a mixture of conformers only one recorded here 7.70 (3H, m); 7.35 (5H, m); 6.60 (2H, d); 5.90 (1H, s); 4.45 (1H, m); 3.85 (1H, m); 3.40 (2H, m); 2.9-2.4 (8H, m); 2.70 (3H, s); 1.60 (2H, m); 1.30 (2H, m); 1.00 (2H, m). MS TOF 465 (M+1<sup>+</sup>).
- 10 Hplc (Luna2 C18, Gradient 3, water/acetonitrile/TFA) rt 8.52 min.

**Assay protocols**

15 **Enzyme Inhibition assays:**

- Enzyme assays were carried out at room temperature in 0.1M phosphate buffer, pH7.4 according to the method of Tapparelli et al (J. Biol. Chem. 1993,268,4734-4741).
- 20 Purified human factor Xa, trypsin, thrombin and plasmin were purchased from Alexis Corporation, Nottingham, UK. Urokinase was purchased from Calbiochem, Nottingham, UK. Chromogenic substrates for these enzymes; pefachrome-FXA, pefachrome-TRY, pefachrome-TH, pefachrome-PL and
- 25 pefachrome-UK were purchased from Pentapharm AG, Basel, Switzerland. Product (p-nitroaniline) was quantified by adsorption at 405nm in 96 well microplates using a Dynatech MR5000 reader (Dynex Ltd, Billingshurst, UK). Km and Ki were calculated using SAS PROC NLIN (SAS
- 30 Institute, Cary, NC, USA, Release 6.11) K<sub>m</sub> values were determined as 100.9μM for factor Xa/pefachrome-FXA and 81.6μM for trypsin/pefachrome-TRY. Inhibitor stock solutions were prepared at 40mM in Me2SO and tested at 500μM, 50μM and 5μM. Accuracy of Ki measurements was
- 35 confirmed by comparison with Ki values of known inhibitors of factor Xa and trypsin.

In agreement with published data, benzamidine inhibited factor Xa, trypsin, thrombin, plasmin and urokinase with Ki values of 155 $\mu$ M, 21 $\mu$ M, 330nM, 200nM and 100nM respectively. NAPAP inhibited thrombin with a Ki value of 3nM. Compounds of the invention were found to have activity in these assays.

#### Partial Thromboplastin Time (Prothrombin) Test Protocol

- 10 Venous blood was collected into 3.2% (0.109M) trisodium citrate vacutainer tubes at 1 volume of anticoagulant to nine volumes of blood. The blood cells were separated by centrifugation at 700g for ten minutes to yield plasma, which was frozen at 70°C until required.
- 15 To perform the test, 100 $\mu$ l of plasma was pipetted into in a glass test tube, 1 $\mu$ l of test compound in DMSO was added, and allowed to warm to 37° over two minutes. 100 $\mu$ l of warm (37°) Manchester (tissue thromboplasin) reagent (Helena Biosciences, UK) was added, allowed to
- 20 equilibrate for two minutes. 100 $\mu$ l of warm (37°) 25mM calcium chloride solution was added to initiate clotting. The test tube was tilted three times through a 90° angle every five seconds to mix the reagents and the time to clot formation recorded. Data from a series
- 25 of observations and test compound concentrations are analysed by a SAS statistical analysis program and a CT2 (Concentration required to double clotting time) for each compound is generated.
- 30 Compounds of the invention were found to significantly elongate the partial thromboplastin time (Prothrombin time).

	Example No.	Conc. necessary to double the prothrombin time ( $\mu\text{M}$ ) <sup>a</sup>
	9	26
	37	6.7
5	42	7.8
	44	11
	47	8.8
	50	9.0
	51	12
10	52	12
	74	8.6
	75	2.1
	76	4.4
	77	6.1
15	78	1.4
	80	3.6
	81	5.8
	82	4.0

20     <sup>a</sup> The concentration quoted is that of the solution which, when added to the other reagents in the assay, doubles prothrombin time. The final concentration in the assay mixture is one third of this value.

25     Compounds of the invention were found to be potent inhibitors of factor Xa.



CCV/GP 00:00:00

321 Ad 30-6-00

Maia A. do/